Lucie S. Lee, Rounak Feigelman, D. Debruyne, J. Spencer, Chenyu Li, Zhitong Liu, Guoying Liu
{"title":"707:利用多路扩增子NGS检测SARS-CoV-2与季节性呼吸道病毒共感染","authors":"Lucie S. Lee, Rounak Feigelman, D. Debruyne, J. Spencer, Chenyu Li, Zhitong Liu, Guoying Liu","doi":"10.1158/1538-7445.AM2021-707","DOIUrl":null,"url":null,"abstract":"The ongoing COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected everyone around the world. Most symptoms of COVID-19 overlap with symptoms of the flu and the common cold. With the approaching flu season, early and accurate detection of these viruses are critical not only to slow the spread of SARS-CoV-2, but also to ensure that patients receive the appropriate care based on their diagnosis, and to keep the healthcare system from becoming overloaded. We designed a next-generation sequencing (NGS) assay to detect the SARS-CoV-2, influenza A H1N1, influenza A H3N2, influenza B, RSV A, and RSV B viruses, and to allow for surveillance and subtype identification. The primers for this multiplex PCR-based method interrogate nearly every gene of each virus. Subsequent sequencing enables not only virus detection but also co-infection detection for these respiratory viruses. In addition, sequencing of virus-positive samples makes it possible to use this assay for mutation and strain analysis. Using the CleanPlex target enrichment technology, we prepared targeted amplicon libraries with human total RNA (50ng) spiked with SARS-CoV-2 synthetic RNA, influenza A synthetic RNA, influenza B synthetic RNA, RSV A RNA, and RSV B RNA (100-10,000 viral genome copies), either individually or in combination. The NGS library preparation protocol includes a reverse transcription step to generate cDNA, followed by a multiplexed PCR step for specific amplification of viral targets. A critical subsequent background cleaning step removes non-specific PCR products, and a final PCR adds sample indices and Illumina sequencing adapters to complete the NGS library preparation. Libraries were sequenced on the Illumina iSeq100 platform, and sequencing metrics as well as virus characterization were determined using Paragon Genomics9s bioinformatics pipeline. Each sample was sequenced at 1,000 average paired-end reads per amplicon. After aligning sequencing reads to each viral genome, we were able to detect nearly every gene of each virus with high specificity. At viral loads of 10,000 copies, 96-100% of amplicons were covered at >100X, and mapped to the intended virus species as well as to the intended subtypes for influenza A and RSV. The assay also accurately identified co-infected samples, which contained equal copies of SARS-CoV-2 and influenza (either A H1N1, A H3N2, or B). In summary, the assay detects multi-target respiratory viruses with high accuracy and specificity. We plan to expand on our findings for this assay9s performance with additional targets, co-infection studies and mutational analysis studies. Citation Format: Lucie S. Lee, Rounak Feigelman, David Debruyne, Julia Spencer, Chenyu Li, Zhitong Liu, Guoying Liu. Detection of SARS-CoV-2 co-infections with seasonal respiratory viruses using a multiplexed amplicon NGS panel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 707.","PeriodicalId":417728,"journal":{"name":"COVID-19 and Cancer","volume":"127 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract 707: Detection of SARS-CoV-2 co-infections with seasonal respiratory viruses using a multiplexed amplicon NGS panel\",\"authors\":\"Lucie S. Lee, Rounak Feigelman, D. Debruyne, J. Spencer, Chenyu Li, Zhitong Liu, Guoying Liu\",\"doi\":\"10.1158/1538-7445.AM2021-707\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The ongoing COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected everyone around the world. Most symptoms of COVID-19 overlap with symptoms of the flu and the common cold. With the approaching flu season, early and accurate detection of these viruses are critical not only to slow the spread of SARS-CoV-2, but also to ensure that patients receive the appropriate care based on their diagnosis, and to keep the healthcare system from becoming overloaded. We designed a next-generation sequencing (NGS) assay to detect the SARS-CoV-2, influenza A H1N1, influenza A H3N2, influenza B, RSV A, and RSV B viruses, and to allow for surveillance and subtype identification. The primers for this multiplex PCR-based method interrogate nearly every gene of each virus. Subsequent sequencing enables not only virus detection but also co-infection detection for these respiratory viruses. In addition, sequencing of virus-positive samples makes it possible to use this assay for mutation and strain analysis. Using the CleanPlex target enrichment technology, we prepared targeted amplicon libraries with human total RNA (50ng) spiked with SARS-CoV-2 synthetic RNA, influenza A synthetic RNA, influenza B synthetic RNA, RSV A RNA, and RSV B RNA (100-10,000 viral genome copies), either individually or in combination. The NGS library preparation protocol includes a reverse transcription step to generate cDNA, followed by a multiplexed PCR step for specific amplification of viral targets. A critical subsequent background cleaning step removes non-specific PCR products, and a final PCR adds sample indices and Illumina sequencing adapters to complete the NGS library preparation. Libraries were sequenced on the Illumina iSeq100 platform, and sequencing metrics as well as virus characterization were determined using Paragon Genomics9s bioinformatics pipeline. Each sample was sequenced at 1,000 average paired-end reads per amplicon. After aligning sequencing reads to each viral genome, we were able to detect nearly every gene of each virus with high specificity. At viral loads of 10,000 copies, 96-100% of amplicons were covered at >100X, and mapped to the intended virus species as well as to the intended subtypes for influenza A and RSV. The assay also accurately identified co-infected samples, which contained equal copies of SARS-CoV-2 and influenza (either A H1N1, A H3N2, or B). In summary, the assay detects multi-target respiratory viruses with high accuracy and specificity. We plan to expand on our findings for this assay9s performance with additional targets, co-infection studies and mutational analysis studies. Citation Format: Lucie S. Lee, Rounak Feigelman, David Debruyne, Julia Spencer, Chenyu Li, Zhitong Liu, Guoying Liu. Detection of SARS-CoV-2 co-infections with seasonal respiratory viruses using a multiplexed amplicon NGS panel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 707.\",\"PeriodicalId\":417728,\"journal\":{\"name\":\"COVID-19 and Cancer\",\"volume\":\"127 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"COVID-19 and Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.AM2021-707\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"COVID-19 and Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-707","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
由严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2)引起的COVID-19大流行正在持续,影响到世界各地的每个人。COVID-19的大多数症状与流感和普通感冒的症状重叠。随着流感季节的临近,这些病毒的早期和准确检测不仅对于减缓SARS-CoV-2的传播至关重要,而且对于确保患者根据诊断得到适当的护理,并防止医疗保健系统变得超负荷至关重要。我们设计了一种新一代测序(NGS)检测方法,用于检测SARS-CoV-2、甲型H1N1流感、甲型H3N2流感、乙型流感、RSV a和RSV B病毒,并进行监测和亚型鉴定。这种基于多重pcr方法的引物几乎询问每种病毒的每个基因。随后的测序不仅可以检测病毒,还可以检测这些呼吸道病毒的共感染。此外,病毒阳性样品的测序使其有可能用于突变和菌株分析。利用CleanPlex靶标富集技术,我们制备了带有人总RNA (50ng)的靶向扩增子文库,其中分别添加了SARS-CoV-2合成RNA、甲型流感合成RNA、乙型流感合成RNA、RSV A RNA和RSV B RNA(100-10,000个病毒基因组拷贝)。NGS文库制备方案包括一个反转录步骤来生成cDNA,然后是一个多重PCR步骤来特异性扩增病毒靶点。关键的后续背景清洗步骤去除非特异性PCR产物,最后的PCR添加样品索引和Illumina测序适配器,以完成NGS文库准备。文库在Illumina iSeq100平台上测序,测序指标和病毒特性使用Paragon genomics的生物信息学管道进行测定。每个样本在每个扩增子的平均配对末端读取1000个序列。在将测序读数与每个病毒基因组对齐后,我们能够以高特异性检测每种病毒的几乎每个基因。在病毒载量为10,000拷贝时,96% -100%的扩增子在>100倍时被覆盖,并映射到预期的病毒种类以及甲型流感和RSV的预期亚型。该方法还能准确识别出含有相同拷贝的SARS-CoV-2和流感病毒(甲型H1N1、甲型H3N2或乙型)的共感染样本。总之,该方法检测多靶点呼吸道病毒具有较高的准确性和特异性。我们计划通过其他靶点、共感染研究和突变分析研究来扩展我们的研究结果。引文格式:Lucie S. Lee, ronak Feigelman, David Debruyne, Julia Spencer,李晨宇,刘志彤,刘国英。应用多路扩增子NGS面板检测SARS-CoV-2与季节性呼吸道病毒共感染[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志,2021;81(13 -增刊):摘要第707期。
Abstract 707: Detection of SARS-CoV-2 co-infections with seasonal respiratory viruses using a multiplexed amplicon NGS panel
The ongoing COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected everyone around the world. Most symptoms of COVID-19 overlap with symptoms of the flu and the common cold. With the approaching flu season, early and accurate detection of these viruses are critical not only to slow the spread of SARS-CoV-2, but also to ensure that patients receive the appropriate care based on their diagnosis, and to keep the healthcare system from becoming overloaded. We designed a next-generation sequencing (NGS) assay to detect the SARS-CoV-2, influenza A H1N1, influenza A H3N2, influenza B, RSV A, and RSV B viruses, and to allow for surveillance and subtype identification. The primers for this multiplex PCR-based method interrogate nearly every gene of each virus. Subsequent sequencing enables not only virus detection but also co-infection detection for these respiratory viruses. In addition, sequencing of virus-positive samples makes it possible to use this assay for mutation and strain analysis. Using the CleanPlex target enrichment technology, we prepared targeted amplicon libraries with human total RNA (50ng) spiked with SARS-CoV-2 synthetic RNA, influenza A synthetic RNA, influenza B synthetic RNA, RSV A RNA, and RSV B RNA (100-10,000 viral genome copies), either individually or in combination. The NGS library preparation protocol includes a reverse transcription step to generate cDNA, followed by a multiplexed PCR step for specific amplification of viral targets. A critical subsequent background cleaning step removes non-specific PCR products, and a final PCR adds sample indices and Illumina sequencing adapters to complete the NGS library preparation. Libraries were sequenced on the Illumina iSeq100 platform, and sequencing metrics as well as virus characterization were determined using Paragon Genomics9s bioinformatics pipeline. Each sample was sequenced at 1,000 average paired-end reads per amplicon. After aligning sequencing reads to each viral genome, we were able to detect nearly every gene of each virus with high specificity. At viral loads of 10,000 copies, 96-100% of amplicons were covered at >100X, and mapped to the intended virus species as well as to the intended subtypes for influenza A and RSV. The assay also accurately identified co-infected samples, which contained equal copies of SARS-CoV-2 and influenza (either A H1N1, A H3N2, or B). In summary, the assay detects multi-target respiratory viruses with high accuracy and specificity. We plan to expand on our findings for this assay9s performance with additional targets, co-infection studies and mutational analysis studies. Citation Format: Lucie S. Lee, Rounak Feigelman, David Debruyne, Julia Spencer, Chenyu Li, Zhitong Liu, Guoying Liu. Detection of SARS-CoV-2 co-infections with seasonal respiratory viruses using a multiplexed amplicon NGS panel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 707.